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Abstract
A new 1:1 drug-drug cocrystal of theophylline (THP) and aspirin (ASP) was successfully prepared by 
liquid assisted grinding, evaporative crystallization and slurry conversion crystallization. The obtained 
cocrystal was comprehensively characterized by Single Crystal X-ray Diffraction, Powder X-ray 
diffraction, Differential Scanning Calorimetry, Thermogravimetric analysis, Scanning Electron 
Microscopy and Fourier Transform Infrared analysis. Ternary phase diagrams (TPDs) were constructed 
for the obtained cocrystal in isopropyl alcohol at two different temperatures, i.e. 20 and 40°C. A narrow 
stability region was found for the pure THP-ASP cocrystal in the phase diagram at both temperatures. 
By proper selection of the ratios between THP, ASP and IPA from the stability region, THP-ASP 
cocrystals could be purely produced by isothermal slurry conversion in IPA. In addition, molecular 
modelling was deployed to provide mechanistic insights into the formation of this THP-ASP cocrystal 
system.
Introduction
Cocrystals are defined as crystalline materials comprised of two or more components that are solids 
under ambient conditions and held together by noncovalent forces.1-2 Pharmaceutical cocrystals which 
include at least one active pharmaceutical ingredient (API) in the crystal lattice are becoming an integral 
part of the pharmaceutical industry. As the components are held together based on intermolecular 
interactions, cocrystals offer the advantage of improving the physicochemical properties of the APIs 
without modifying their structural integrity. Hence, the design of new solid forms of APIs, with 
improved physicochemical properties like stability, melting point, hygroscopicity and solubility by 
cocrystallization has gained a wide interest.3-7 
Cocrystal manufacture with a high purity and yield is a challenging task because thermodynamic and 
kinetic aspects of cocrystal formation remain poorly understood.8 However, in recent years, 
construction of ternary phase diagrams (TPDs) has helped to address such issues. TPDs are useful to 
determine the stability region of a desired cocrystal in a specific solvent and offer the corresponding 
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stoichiometric ratios of individual components for pure cocrystal formation.9-13 They are also 
specifically important for development of crystallization methodologies.14 Recently, Chiarella et al. 
have explained the importance of TPDs for the development of preparative procedures for solution 
crystallization, using 1:1 stochiometric ratio of trans-cinnamic acid and nicotinamide as a model 
cocrystal.9 In some cases, the construction of TPDs has led to the discovery of new solid forms of 
cocrystals for specific systems. For instance, Chadwick et al. found a new solid form of urea–glutaric 
acid cocrystal when they constructed the TPD in H2O.10 Moreover, TPDs assisted the identification of 
the stability region of a new equimolar cocrystal of p-toluenesulfonamide and triphenylphosphine oxide 
which was previously known to form one cocrystal of 3:2 ratio.11 
As an emerging subset of cocrystals, drug-drug cocrystals are made up of two APIs that may not only 
lead to the modification of the physicochemical properties, but also present new opportunities for the 
development of synergistic therapies.15 In addition, drug-drug cocrystals are more patent eligible since 
they fulfil the criteria of novelty, utility and unpredictability.16 However, this domain remains 
underexplored due to the complexity in their design and preparation.17 Consequently, there is a strong 
interest and demand to develop cocrystallization methods for drug-drug cocrystals.
Theophylline (THP) is a well-studied component that has been used in the synthesis of various types of 
cocrystals.18-20 It is used in the treatment of respiratory diseases, such as asthma therapy.20 It is the major 
metabolite of caffeine and can be found in tea, coffee, cocoa beans and chocolate.21 THP has four 
anhydrous polymorphs, among which pholymorph II is kinetically stable at room temperature and 
commercially available. It also has a monohydrated form that occurs frequently due to the hygroscopic 
nature of THP.22-29 The structure of THP molecule is shown in Figure 1. It has an imidazole proton, an 
imidazole nitrogen and two carbonyl groups (one donor and three acceptors) that play significant roles 
in the formation of hydrogen bonds, which in turns facilitates the synthesis of numerous types of 
cocrystals with different coformers. It has been proven that the hygroscopic nature of THP was 
restrained by cocrystallization with different types of acid coformers via the formation of O–
H(carboxyl)···N(imidazole) and N-H(imidazole)···O=C(carboxyl) hydrogen bonds.20
Aspirin (ASP) is considered as GRAS (generally regarded as safe ) API that has been employed as a 
coformer in pharmaceutical cocrystals.30 It is an acetyl derivative of salicylic acid (Figure 1), which is 
mainly used in the treatment of pain, inflammation and fever. ASP is known to have three polymorphs, 
among which polymorph I is the stable phase under ambient condition.31-34 Moreover, the ASP molecule 
contains the carboxylic acid functional group which acts as a hydrogen bond acceptor and donor. The 
ΔpKa difference between the THP and ASP is -1.8 (pKa is 1.7 for protonated THP35 and 3.5 for ASP36), 
hence, THP has the affinity to form a cocrystal with ASP through N–H···O and O–H···O intermolecular 
interactions.
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Accordingly, in this work, we present a new 1:1 THP-ASP cocrystal which can be synthesized by 
multiple methods. The obtained cocrystal was characterized comprehensively and its structure was 
successfully solved. Furthermore, molecular modelling was also carried out to understand the 
mechanism of its formation.
Figure 1. Molecular structures of both theophylline and aspirin molecules.
Experimental Section
Materials and methods
Commercially available THP and ASP (catalogue numbers: J60203.5H and A12488.36 respectively) 
were purchased from VWR, Alfa Aesar and used as received. The solvent IPA was purchased from 
VWR, and used without further purification. 
Neat and liquid assisted grinding 
Equimolar amounts of ASP and THP were ground using a mortar and pestle for 30 min. Liquid assisted 
grinding (LAG) was performed in a similar way as neat grinding (NG) method except a few drops of 
IPA were added.
Ball milling (BM) 
BM experiments were performed using a Retsch MM400 ball mill. Equimolar amounts of THP and 
ASP were placed in 25 mL jars containing a 15 mm stainless steel ball per jar. The mill was operated 
at 25 Hz frequency for 30 min.
Preparation of single crystals 
A mixture of THP and ASP (1.5 g, molar ratio 2 : 3) was slurried in 4 mL IPA at 40°C for 24 h. It was 
then filtered and left for partial evaporation until crystals suitable for single crystal X-ray diffraction 
(SCXRD) experiments were obtained.
Solubility studies 
The solubilities for THP and ASP were measured gravimetrically in IPA at 20 and 40°C respectively. 
An excess amount of each solid was added to the solvent at the required temperature and agitated in a 
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Cambridge Reactor Polar Bear Plus instrument. Agitation was then stopped after 24 h and the solid was 
allowed to settle down for 1 h. 
A volume of the sample was filtered using a syringe filter and injected into a preweighed glass vial (W1) 
and then weighed (W2). After allowing the solvent to evaporate, the glass vial was put in an oven at 
50°C overnight. The dry weight (W3) of the vial was recorded after it was allowed to cool down to room 
temperature (RT). From this final dry mass and the mass of the initial solution, the solubility at the 
given temperature was calculated using the formula below:
The solubility = (W3-W1)/(W2-W3) (g of solid/g of solvent) (1)
Construction of the Ternary Phase Diagrams
Slurries of different compositions of THP and ASP in IPA were produced in 30 mL glass vials and 
agitation was provided by using 10 mm magnetic stirrer bars. The vials were placed in Cambridge 
Reactor Polar Bear Plus instrument at the specified temperatures (20 and 40°C) for 24 h. Aliquots of 
solutions were withdrawn after 24 h and the concentrations of THP and ASP were determined by HPLC. 
Mass fractions of each substance in the generated IPA solutions were calculated and then plotted on a 
ternary axis diagrams to generate the appropriate TPDs using ProSim Ternary Diagram software. 
Eutectic points (Eu) or known as invariant points are fixed solution concentrations at which two solid 
phases co-exist together in equilibrium. At each temperature, two eutectic points are determined: i) at 
THP and cocrystal region, Eu1 and ii) at ASP and cocrystal region, Eu2. They were determined using 
the method described by Rodriguez-Hornedo et al,5 by generating a slurry of the two mentioned solid 
forms at each point for 24 h. 
HPLC Analysis
HPLC was used for the measurement of solubility of THP and ASP in IPA at 20 and 40°C, respectively. 
The HPLC system was an Agilent 1260 HPLC (Agilent Technologies, Waldbronn, Germany) plus 
G1311B Quaternary pump, G4212B UV-vis photodiodearray detector, G1322 degasser and Agilent 
HPLC workstation. The column (Kromasil 250 mm × 4.6 mm, 5 μm) was used for analysis and freshly 
prepared acetonitrile: acidic H2O (adjusted pH=3 using ortho-phosphoric acid) (50:50) was set as the 
mobile phase. The flow rate was 0.75 mL∙min-1 with simultaneous multichannel UV detection at 260 
nm. The injection volume for each sample was 5 µl per sample. 
Powder X-ray Diffraction (PXRD)
PXRD patterns were recorded on a PANalytical EMPYREAN diffractometer system using 
Bragg−Brentano geometry and an incident beam of Cu Kα radiation (λ = 1.5418 Å). Room temperature 
scans were performed on a spinning silicon sample holder. The diffraction patterns were collected at 40 
kV and 40 mA, over a 2θ range from 5-30º, with a scan speed of 0.32857º/s.
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Single Crystal X-ray Diffraction (SCXRD)
Suitable single crystals were chosen for SCXRD measurements. The data were collected on a Bruker 
D8 Quest diffractometer with Mo (λ = 0.71073 Å) sealed tube source at 298 K. The data reduction was 
performed using Bruker SAINT software. Crystal structures were solved by direct methods using 
SHELXS and refined by full-matrix least-squares on F2 with anisotropic displacement parameters for 
non-H atoms using SHELXL. Hydrogen atoms associated with carbon atoms were fixed in 
geometrically constrained positions. Hydrogen atoms associated with oxygen and nitrogen atoms were 
included in the located positions. 
Variable temperature PXRD (VT-PXRD)
For VT-PXRD experiments, reflections were collected on Panalytical X’Pert diffractometer (40 kV, 40 
mA, Cu Kα1,2, λ = 1.5418 Å) at 10 ºC intervals from 120 to 150°C by heating at 10°C∙min-1 under N2 
atmosphere. Water cooling system was adopted to control the temperature. Diffraction patterns were 
collected in the 2θ range of 5-30º. PXRD patterns were also collected at 25°C before and after heating.
Thermogravimetric analysis (TGA)
A Q50 TGA from TA instruments was used for the TGA analysis. Experiments were performed using 
aluminium pan under a controlled N2 environment (40 mL∙min-1) over a temperature range of 30-550°C 
with a heating rate 10°C∙min-1. The results were further analyzed by using TA instruments Universal 
2000 software (Universal V4. 5A).
Differential Scanning Calorimetry (DSC)
Netzch proteus instrument was used to perform the thermal analysis for THP, ASP and THP-ASP 
samples. Experiments were carried out by using crimped aluminium pan which contains a certain 
amount of each sample (~5 mg). The experiments were performed over a temperature range of 40 – 
280°C at a heating rate of 10°C∙min-1 under N2 atmosphere (30 mL∙min-1). 
Scanning electron microscopy (SEM)
SEM analysis was performed using SU 70 Hitachi instrument. The samples were coated with gold for 
2 min at 20 mA.
Fourier Transform Infrared (FTIR) Spectroscopy
FTIR spectra were recorded using Perkin Elmer spectrometer. 12 scans were recorded over a spectral 
range of 400 - 4000 cm-1.
Molecular Modelling
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Density functional theory (DFT) calculations were applied using a Gaussian 09 package37 to estimate 
the interaction strength of THP, ASP, and THP-ASP dimers. The equilibrium geometries (gas-phase) 
are calculated with a B97-D3 Grimme’s functional38 and a Gaussian-type 6-31G(d,p) basis set.39 The 
binding energy in each dimer is calculated as follows:
ΔEbind = EAB – (EA + EB)    (2)
where EAB is the energy of a dimer AB while EA and EB are energies of the isolated molecules A and B, 
both being in fully relaxed gas-phase geometries. The energies are calculated using a double hybrid 
B2PLYP-D3 functional,40 which combines exact Hartree-Fock exchange with a MP2-like correlation 
and long-range dispersion corrections; here a basis set of quadruple-ζ valence quality (def2-QZVPP) 
was used.41 This methodology has been successfuly applied for small and medium-sized API molecules 
in recent studies such as salicylic acid,42 parabens,43 risperidone,44 clofazimine,45 and carbamazepine.46 
Results and Discussion 
PXRD patterns of solids recovered from neat grinding indicated that a new solid phase was formed but 
significant amounts of starting materials remained (Figure 2a). When a few drops of IPA were added 
to assist the grinding, the PXRD pattern shows all the main peaks of THP were no longer present and a 
new solid phase was formed although some peaks were overlapping with those from ASP. This phase 
can be also prepared by ball milling (BM) assisted with IPA for 30 min. To check if ASP remained in 
the new phase, DSC experiments were carried out as shown in Figure 2b, which revealed that the onset 
melting temperature of the new phase is 143°C, which drops between the melting points of the 
individual components (THP–272°C, and ASP–141°C). There is no endothermal eutectic peak present 
in the new phase, indicating that the equimolar ASP and THP mixture fully transformed to the new 
phase. Thus, we assumed that the new phase is a 1:1 ratio of THP-ASP cocrystal. 
Figure 2. (a) PXRD patterns of ASP, THP and products prepared by neating grinding, IPA assisted 
grinding and IPA assisted BM, respectively. (b) DSC profiles of ASP, THP and the product prepared 
by IPA assisted BM.
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To verify our assumptions, single crystals were isolated by evaporative crystallization from IPA. 
SCXRD analysis revealed that the obtained THP–ASP cocrystal crystallizes in the triclinic P-1 space 
group (see Table S1 for full crystallographic information), with one molecule of each component 
present in the asymmetric unit (Figures 3). The ORTEP diagram of THP-ASP cocrystal is provided in 
Figure S1. The imidazole hydrogen atom of THP forms a strong N-H···O hydrogen bond with the 
carboxylic oxygen of ASP while the carboxylic hydrogen atom of ASP froms another strong O-H···O 
hydrogen bond with the carbonyl oxygen of THP. The two hydrogen bonds lead to a  ring in the 𝑅22(9)
heterodimer. Further, two THP-ASP dimers are connected with each other via moderate C-H (phenyl, 
ASP)···O (carbonyl, THP) hydrogen bonds, forming a four-molecule cluster (Figure S2). Moreover, 
the clusters can be repeatedly connected by each other via weak C-H (methyl, ASP)···O (carbonyl, 
THP) hydrogen bonds, resulting in a 1D tape-like chain (Figure S3). The distances, angles and 
strengthes of hydrogen bonds are listed in Table S2. As expected, the calculated PXRD pattern from 
SCXRD data matches well with those experimental PXRD data for IPA assisted grinding and ball 
milling (Figure 4).
Figure 3. The structure of 1:1 THP-ASP cocrystal, the red dash lines stand for N–H···O and O–H···O 
hydrogen bonds.
Figure 4. The calculated PXRD pattern of THP-ASP cocrystal (black line) and experimental PXRD 
pattern for IPA assisted BM product (red line).
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The solubilities of THP and ASP were determined by gravimetric method in IPA at 20°C and 40°C, 
respectively, and the values are listed in Table 1. The solubility of ASP is much higher than THP by 
factors of 43 and 48 times at 20°C and 40°C, respectively. 











20 2.27±0.14 0.0126 96.1±2.7 0.5339
40 5.60±0.01 0.0326 241±4 1.3389
The two invariant (eutectic) points were determined experimentally and listed in Table 2 and Table 3 
at 20 and 40°C respectively.
Table 2. Invariant points at 20°C.

















Point 1 THP and THP-
ASP cocrystal 0.0037 0.0467 0.9495 0.0170 0.2146
Point 2 ASP and THP-
ASP cocrystal 0.0018 0.0939 0.9043 0.0086 0.4530
Table 3. Invariant points at 40°C.

















Point 1 THP and THP-ASP cocrystal 0.0079 0.1235 0.8685 0.0399 0.6206
Point 2 ASP and THP-ASP cocrystal 0.0050 0.2006 0.7944 0.0274 1.1015
Construction and interpretation of ternary phase diagrams 
In order to gain some insights into the thermodynamics of the THP-ASP cocrystal system, TPDs were 
constructed at 20 and 40°C in IPA respectively (Figure 5 and Figure 6). For clarity, the diagrams were 
plotted using mass fractions. Both diagrams show unsymmetrical behaviour, a trend that is common 
when there is a wide difference in solubility between the pure drug and coformer.9 
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Figure 5. Ternary phase diagram (Left) and the expansion of the top diagram (Right) for the 
THP−ASP−IPA system at 20°C. 
The TPD at 20°C (Figure 5) is divided into six regions. Region 1 represents an undersaturated solution. 
Regions 2, 3 and 4 signify a solution in equilibrium with the solid phases of THP, THP-ASP cocrystal 
and ASP respectively. As for regions 5 and 6, they represent the coexistence of cocrystal with THP and 
ASP respectively. 
The region of cocrystal stability (region 3) is skewed toward the ASP axis as its solubility is much 
higher than the solubility of THP. The 1:1 component stoichiometric line does not intersect the 
solubility curve for the 1:1 cocrystal, resulting an incongruent phase diagram. This implies that for an 
equimolar mixture of THP and ASP, one cannot get a suspension of pure THP-ASP cocrystals no matter 
how much IPA is used. Because the cocrystal phase on its own will transform either to the mixture of 
cocrystal and THP (zone 5) or to THP (Zone 2) according to the amount of solvent used. As a result, 
the solubility of the cocrystal cannot be readily determined as it transforms to the most stable drug form 
in solution.5 
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Figure 6. Ternary phase diagram (Left) and the expansion of the top diagram (Right) for the 
THP−ASP−IPA system at 40°C.
The same regions are present at 40°C (Figure 6). However, at higher temperature, the solubility of both 
THP and ASP increased and the diagram was pushed downward ,making the liquidus region more 
significant and clear. It is found that temperature has  significant effects on the size and position of the 
thermodynamic stability regions. For instance, the cocrystal region became more skewed toward the 
ASP axis, the distance between the solvent apex and the cocrystal solubility curve became longer and 
the undersaturated region occupied a larger area. Obviously, increasing temperature has increased the 
solubilities of both drugs by different amounts which resulted in an increase in the difference between 
the solubilities and therefore making the diagram even more asymmetric. Although the cocrystal still 
dissolved incongruently, pure single crystals can be prepared by choosing the appropriate point from 
the diagram.
Isothermal slurry cocrystallisation
To check the reliability of TPDs, two combination points ‘cc1’ and ‘cc2’ from region 3 at each 
temperature were selected to prepare THP–ASP cocrystal by isothermal slurry conversion 
crystallization method in IPA. The PXRD patterns of cocrystals obtained from this method match well 
with the calculated PXRD pattern (Figure 7a). DSC analysis (Figure 7b) also reveals the purity of THP-
ASP cocrystal. TGA profiles show that the decomposition of the cocrystal starts around 145°C, 
comparable with that of ASP but with different mass loss rate. VT-PXRD data is also consistent with 
TGA, where the cocrystal dissociates at 150°C, suggesting the formation of THP crystals after the ASP 
decomposition (Figure 8). The FTIR spectrum of the THP-ASP cocrystal is, to a large extent, a 
superposition of the ASP and THP spectra. The major difference is the presence of a high-intensity 
band at 1631 cm-1, which in ASP and THP appears as a low-intensity shoulder (Figure S4). SEM 
analysis was carried out to visualise and compare the external appearance of ASP, THP and the newly 
formed cocrystal (Figure S5). It shows that ASP presents flat block crystal habit and THP presents as 
elongated needle shape. However, the new THP-ASP cocrystal could be differentiated by its distinct 
polyhydral shape.
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Figure 7. (a) PXRD patterns and (b) DSC curves of the obtained cocrystal using isothermal slurry 
conversion crystallization method at 20 and 40°C 
Figure 8. (a) TGA analysis of THP, ASP and THP–ASP cocrystal; (b) VT-PXRD of the prepared 
THP-ASP cocrystal.
Mechanistic insight
In effort to gain a molecular-level understanding of the formation of THP‒ASP cocrystal, we calculated 
the binding energies in dimers of THP, ASP and the resultant THP-ASP cocrystal by density function 
theory (Figure 9). Our computations show that THP dimer (F II) comprises a strong N‒H…N and a weak 
C=O…H‒C hydrogen bonding (ΔEbind = -46.9 kJ/mol). ASP dimer (F I) forms a centrosymmetric H-
bonded dimer due to interactions of its carboxyl groups; this results in creation of two strong C=O…H‒O 
H-bonds and yields ΔEbind = -66.9 kJ/mol. The THP‒ASP dimer is stabilised by binding energy of -71.2 
kJ/mol, which results from interactions of two strong H-bonds: C=OTHP…H‒O and C=OASP…H‒N. Thus, 
the order of bonding energy is THP dimer (F II) < ASP dimer (F I) < THP‒ASP dimer, rationalising 
the formation potential of THP-ASP solid.
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Figure 9. DFT binding energy calculated for dimers of THP (F II), ASP (F I), and THP-ASP cocrystal. 
Conclusion
A new 1:1 drug-drug cocrystal of THP-ASP was synthesised and characterized. The construction of 
TPDs clearly identified the stability regions for pure THP-ASP cocrystal formation in IPA at 20 and 
40°C, allowing the rationalization of the experimental conditions for future manufacture. The TPDs 
indicated that THP-ASP cocrystal was stable in a narrow region in IPA. The melting point of THP-ASP 
cocrystal is much closer to that of ASP rather than THP. The new cocrystal displayed different crystal 
habit to the starting materials. The mechanistic insight behind the cocrystal formation was also studied 
and the preferential formation of THP-ASP cocrystals was proved by DFT binding energy calculations. 
Supporting Information
X-ray crystallographic information, supplementary figures of crystal structures, FTIR and SEM images are 
available in SI. The cif file for the THP-ASP cocrystal have been deposited with the Cambridge 
Crystallographic Data Centre, CCDC number 1821703.
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